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High mobility group box 1 (HMGB1) is a widely-expressed and highly-abundant protein
that acts as an extracellular signal upon active secretion by immune cells or passive
release by dead, dying, and injured cells. Both intracellular and extracellular HMGB1 play
pivotal roles in regulation of the cellular response to stress. Targeting the translocation,
release, and activity of HMGB1 can limit inflammation and reduce tissue damage during
infection and sterile inflammation. Although the mechanisms contributing to HMGB1
biology are still under investigation, it appears that oxidative stress is a central regulator
of HMGB1’s translocation, release, and activity in inflammation and cell death (e.g.,
necrosis, apoptosis, autophagic cell death, pyroptosis, and NETosis). Thus, targeting
HMGB1 with antioxidant compounds may be an attractive therapeutic strategy for
inflammation-associated diseases such as sepsis, ischemia and reperfusion injury,
arthritis, diabetes, and cancer.
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Introduction
High mobility group box 1 (HMGB1), a widely-expressed and highly-abundant protein, plays
multiple roles in physiological and pathological processes and is implicated in human health
and diseases (Kang et al., 2014a), especially aging (Huang et al., 2014b) and inflammation-
associated diseases (Andersson and Tracey, 2011; Harris et al., 2012). HMGB1 was first identi-
fied in 1973 as a non-histone nuclear protein containing two DNA-binding HMG box domains
(N-terminal A and central B) and an acidic C-terminal tail (Goodwin et al., 1973). Nuclear
HMGB1, as an architectural factor, sustains chromosome structure and stability. Loss of HMGB1
in vitro and/or in vivo leads to a number of abnormalities in nuclear structure and function,
such as genomic instability (Giavara et al., 2005), abnormal gene transcription (Rowell et al.,
2012), impaired DNA damage response (Lange et al., 2008), impaired genome chromatiniza-
tion (Celona et al., 2011), and inflammatory nucleosome release (Kang et al., 2014c). Under
stress conditions, HMGB1 translocates from the nucleus to the cytosol and then releases into
the extracellular space (Zhang et al., 2013). Cytosolic HMGB1, as a Beclin-1-binding protein,
promotes autophagy, an evolutionarily-conserved and strictly-regulated lysosomal degradation
pathway (Tang et al., 2010b). In some cases, HMGB1 presents in the cell membrane, contribut-
ing to neurite outgrowth, platelet activation, and cell adhesion. HMGB1 has not only intracel-
lular functions, but also many extracellular functions such as cytokine and chemokine activ-
ity, which are mediated by HMGB1 receptors [e.g., receptor for advanced glycation end prod-
ucts (RAGE) (Hori et al., 1995), toll-like receptors (TLRs, such as TLR2, TLR4, and TLR9)
(Park et al., 2004; Tian et al., 2007)] or endocytic HMGB1 uptake (Kang et al., 2014b; Xu
et al., 2014a) to activate the downstream signaling pathway (e.g., nuclear factor-κB, interferon
regulatory factor-3 and phosphatidylinositol 3-kinase) (Lotze and Tracey, 2005). Other aspects
Yu et al. Oxidative stress and HMGB1
of HMGB1, such as post-translational modification [e.g., acety-
lation (Bonaldi et al., 2003) and phosphorylation (Youn and
Shin, 2006), cleavage (Leblanc et al., 2014), and degradation (Li
et al., 2011), as well as its binding partners (Bianchi, 2009), are
also involved in the regulation of extracellular HMGB1 activity.
HMGB1 global knockout mice die shortly after birth (Calogero
et al., 1999), whereas HMGB1 conditional knockout/knockin
mice exhibit a tissue-dependent phenotype under various stres-
sors (Kitahara et al., 2008; Yanai et al., 2013; Huang et al., 2014a;
Huebener et al., 2014; Kang et al., 2014c). Collectively, these find-
ings suggest that HMGB1 plays a location- and modification-
dependent role with fine-tuned mechanisms (Andersson et al.,
2014).
Although the mechanisms for regulating HMGB1 release and
activity vary depending on context, experimental studies reveal
that oxidative stress is likely a common mechanism regulating
HMGB1 translocation, release, and activity (Tang et al., 2011c).
Oxidative stress is defined as an imbalance between the produc-
tion of reactive oxygen species (ROS) and antioxidant defenses.
Mild oxidative stress has been demonstrated to promote cell sur-
vival, whereas severe oxidative stress has been demonstrated to
cause oxidative injury and even death. ROS, including superoxide
anion (O−2 ), hydroxyl radical (OH), hydrogen peroxide (H2O2),
and singlet oxygen (1O2), are primarily generated by mito-
chondria and NADPH oxidases (NOXs). Mitochondrion is not
only an ROS production source, but also contains antioxidants.
Mitochondrial dysfunction and NOX abnormality have been
implicated in the etiology of numerous common diseases and
aging (Finkel and Holbrook, 2000). This review describes recent
advances in our understanding of oxidative stress-mediated regu-
lation of HMGB1 biology in inflammation and cell death (Green
et al., 2009; Linkermann et al., 2014).
Oxidative Stress-Mediated HMGB1
Release
Infection
Sepsis is a systemic inflammatory response syndrome often
caused by microbial infection or an inflammatory insult that
induces the release of early and late response pro-inflammatory
cytokines from immune (e.g., macrophages and monocytes) and
non-immune (e.g., endothelial) cells (Angus and Van Der Poll,
2013). Early response cytokines [e.g., tumor necrosis factor and
interleukin (IL)-1β] peak within the first hours after infection;
circulatory levels then revert to near baseline in 3–4 h (Tracey and
Cerami, 1993). HMGB1 is one of the delayed response cytokines,
secreted by immune cells 20 h after activation with lipopolysac-
charide (Wang et al., 1999). In vivo, HMGB1 is first detectable
in the circulation 8 h after the onset of lethal endotoxemia and
sepsis, subsequently increasing to plateau levels from 16 to 32 h
(Wang et al., 1999). Targeting HMGB1 rather than early response
cytokines provides a wider time window for clinical intervention
to prevent lethal sepsis (Wang et al., 2008, 2014).
HMGB1 cannot be actively secreted via the classical endo-
plasmic reticulum-Golgi secretory pathway due to lack of a
leader signal sequence. Instead, several mechanisms have been
reported to be involved in active HMGB1 secretion in acti-
vated immune cells. These mechanisms include chromosome
regionmaintenance 1 (CRM1)-mediated nuclear export (Bonaldi
et al., 2003), the lysosome-mediated secretory pathway (Gardella
et al., 2002), pyruvate kinase M2 isoform-mediated metabolism
reprogramming (Yang et al., 2014), and double-stranded RNA-
activated protein kinase (PKR)-mediated inflammasome acti-
vation (Lu et al., 2012), as well as oxidative stress-mediated
mitogen-activated protein kinases and nuclear factor-κB path-
ways (Tang et al., 2007b). Antioxidants such as quercetin (Tang
et al., 2009), edaravone (Kato et al., 2009), epigallocatechin gal-
late (Li et al., 2007), and resveratrol (Xu et al., 2014b) significantly
inhibit HMGB1 release in animal models of sepsis, suggesting
that oxidative stress mediates HMGB1 secretion during infec-
tion. Indeed, H2O2 at nontoxic doses (e.g., 0.0125–0.125mM)
can directly induce HMGB1 cytoplasmic translocation and acti-
vate release in macrophages and monocytes (Tang et al., 2007b).
However, the effects of other ROS resources on HMGB1 release
remain unexplained.
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) was
recently identified as a general regulator of the anti-oxidative
stress response by inducing the expression of a number of
antioxidant response element-dependent genes such as heme
oxygenase-1 (HO-1), a rate-limiting enzyme in the catabolism
of heme. Suppression of NRF2 or HO-1 significantly increases
oxidative injury and HMGB1 release, whereas upregulation of
HO-1 inhibits HMGB1 release in infection (Kawahara et al., 2009;
Takamiya et al., 2009; Tsoyi et al., 2009) (Figure 1A). Induction
of HO-1 by NRF2 requires activation of p38 mitogen-activated
protein kinases, confirming crosstalk between inflammation and
the antioxidative response (Park et al., 2013). Thus, activation of
the NRF2 pathway may have a therapeutic effect in inflammatory
disease.
Heat shock proteins (HSPs) are highly-conserved and present
in cells under normal conditions, but are overexpressed under
some specific stress conditions such as temperature jump and
infection. Induction of the heat shock response can suppress
lipopolysaccharide-induced HMGB1 release in macrophages
(Tang et al., 2005). HSP72, the main stress-induced HSP, inhibits
oxidative stress-induced HMGB1 release by direct protein-
to-protein interaction in macrophages (Tang et al., 2007a)
(Figure 1A). Although these findings identify an essential role for
HSP72 in blocking inflammation and preventing HMGB1 release
in activated macrophages, it is not known whether an impaired
heat shock response contributes to HMGB1 release in other cells.
Sterile Inflammation
Inflammation after tissue injury (e.g., ischemic, trauma, and
transplant) in the absence of pathogens has been recognized
for a long time and involves many changes, including release
of endogenous damage-associated molecular patterns (DAMPs)
(Tsung et al., 2014). Compared with pathogen-associated molec-
ular patterns (PAMPs), which are non-self-molecules, DAMPs
are self-molecules with the ability to activate inflammation
via pattern recognition receptors. HMGB1 is a typical DAMP
and mediates the sterile inflammatory response in response to
ischemia/reperfusion (I/R) injury to multiple tissues such as liver
(Tsung et al., 2005), heart (Andrassy et al., 2008), kidney (Wu
et al., 2010), brain (Kim et al., 2006), and intestine (He et al.,
2012). I/R injury is tissue damage caused when blood supply
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FIGURE 1 | Oxidative stress-mediated HMGB1 release in infection,
inflammation, and cell death. (A) CRM1-mediated nuclear export of
HMGB1 in activated immune cells. (B) PARP1-medaited HMGB1
release in necrosis. (C) Caspase3/7-medaited HMGB1 release in
apoptosis. (D) ATG5-medaited HMGB1 release in autophagy. (E)
PKR-mediated HMGB1 release in pyroptosis. (F) PAD4-mediated
HMGB1 release in NETosis. The image is modified from Kang et al.
(2013).
returns to tissue after a period of ischemia or lack of oxygen.
Unlike in sepsis, HMGB1 levels are increased as early as 1 h after
I/R injury and then increase in a time-dependent manner for up
to 24 h (Tsung et al., 2005). Although several receptors (e.g., TLRs
and RAGE) contribute to HMGB1 activity in I/R injury, TLR4
appears to be the dominant receptor for HMGB1-induced sterile
inflammation in the liver (Tsung et al., 2005).
The release of HMGB1 during liver I/R is not only mainly
caused by cell death, but may also be an active process reg-
ulated by ROS signaling (Tsung et al., 2007). Antioxidants
N-acetyl-L-cysteine or Trolox inhibit hypoxic (1% oxygen)-
or H2O2-induced HMGB1 release in hepatocytes in vitro and
in vivo (Tsung et al., 2007). Remarkably, the calcium/calmodulin-
dependent protein kinase type IV- and β -mediated calcium-
dependent signaling pathways are downstream of oxidative
stress, allowing HMGB1 release in I/R. Genetic and phar-
macologic inhibition of calcium/calmodulin-dependent protein
kinases inhibits HMGB1 release and protects against liver I/R
injury (Tsung et al., 2007). Inhibition of HMGB1 activity by
injection of neutralizing antibody partially abolishes the increase
in liver manganese superoxide dismutase, a key mitochondrial
antioxidant enzyme, after I/R (Pardo et al., 2008). In addition to
inhibiting HMGB1 release in sepsis, activation of the NRF2-HO1
pathway also limits HMGB1 release and protects against I/R
injury and other sterile inflammatory injuries (Yun et al., 2010;
Wang et al., 2013) (Figure 1A). Considering these findings
together, oxidative stress-induced calcium signaling facilitates
HMGB1 release in sterile inflammation.
Necrosis
In its default form, necrosis is a type of unexpected and accidental
cell damage lacking the morphological characteristics of apopto-
sis or autophagy (Galluzzi et al., 2012). A very large number of
chemicals or physical stimuli (e.g., toxins, radiation, heat, trauma,
alcohol, drugs, and I/R injury) can cause necrosis. The release
of intracellular contents, including HMGB1, after cellular mem-
brane damage is the cause of inflammation in necrosis (Scaffidi
et al., 2002). It is assumed that adenosine triphosphate (ATP)
depletion from overactivation of ADP ribose polymerase (PARP)
causes necrosis (Ha and Snyder, 1999). The best known member
of the PARP family is a DNA nick sensor enzyme that becomes
activated by DNA breaks. Excessive DNA damage during oxida-
tive injury triggers PARP-mediated necrosis. Knockout of PARP1
in cells inhibits oxidative injury-induced HMGB1 release follow-
ing necrosis in response to DNA damage (Ditsworth et al., 2007)
(Figure 1B). PARP1 deficiency in mice and PARP inhibitors pro-
tect against stroke, I/R injury, sepsis, diabetes, and pancreati-
tis, suggesting that PARP1 is a potential target in inflammatory
disease (Giansanti et al., 2010; Luo and Kraus, 2012).
In addition to the classic, unregulated form of necrosis, a form
of regulated cell death, namely necroptosis, also exists (Galluzzi
et al., 2012). The core components of the necroptosis machin-
ery include receptor-interacting protein kinase (RIPK)-1, RIPK3,
and themixed lineage kinase domain-like protein (MLKL) (Link-
ermann and Green, 2014). Upon ligand binding, RIPK1 is
recruited to tumor necrosis factor receptor superfamily and TLR
complexes, promoting pro-survival and inflammatory signal-
ing. RIPK1 also directly regulates caspase-8-mediated apopto-
sis or, if caspase-8 activity is blocked, RIPK3-MLKL-dependent
necroptosis. Loss of RIPK1, RIPK3, and MLKL in mice pro-
tects against acute inflammation injury associated with decreased
serum HMGB1 levels (Kaczmarek et al., 2013; Lau et al.,
2013; Dannappel et al., 2014; Murakami et al., 2014). Oxidative
stress is involved in execution of necroptosis downstream of
RIPK1 activation (Vanden Berghe et al., 2014). Necrostatin 1, an
inhibitor of necroptosis, inhibits ROS accumulation andHMGB1
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release/activity in experimental animal models of sepsis and I/R
injury (Duprez et al., 2011; Zhang et al., 2014). Moreover, the
activity of PARP1 is regulated by RIPK1/RIPK3 in necropto-
sis, suggesting that interplay between PARP and RIPK can con-
trol necroptosis (Jouan-Lanhouet et al., 2012). One of the most
active pursuits of cell death research is to elucidate the necrop-
totic pathway in the regulation of DAMP release, as well as the
inflammatory response.
Apoptosis
Apoptosis is the process of programmed cell death thatmay occur
in a wide variety of physiological and pathological situations. It
is often stated that apoptotic cell death doesn’t provoke inflam-
mation due to the cell membrane remaining intact and because
apoptotic cells are rapidly phagocytosed by macrophages. Inter-
estingly, HMGB1 was originally identified as a marker to distin-
guish between necrosis and apoptosis because HMGB1 is only
released in necrosis, but not apoptosis, even after undergoing
secondary necrosis and partial autolysis (Scaffidi et al., 2002).
However, recent studies suggest that HMGB1 can be released
in apoptosis by macrophages, cancer cells, and other cells (Bell
et al., 2006; Jiang et al., 2007). DNA fragmentation is a marker
of apoptosis that allows the release of nucleosomes (histones
and DNA) and HMGB1 into the cytoplasm and extracellular
space. Moreover, HMGB1 release is observed in macrophages
during phagocytic clearance of apoptotic cells in sepsis (Qin et al.,
2006). HMGB1 released from apoptotic cell death is an important
mediator of immunogenic cell death in cancer therapy by TLR4
(Apetoh et al., 2007).
The activity of HMGB1 release in apoptosis is context-
dependent. Oxidative stress is likely to diminish the immune
activity of HMGB1 in apoptosis. Caspases, a family of cys-
teine proteases, are the central regulators of apoptosis. Activated
caspase-3 and -7 in the mitochondrial apoptotic pathway can
cleave NADH dehydrogenase Fe-S protein-1, the 75 kDa subunit
of respiratory complex I. This process leads to a loss of ATP and
the generation of ROS. As a redox-sensitive protein, HMGB1
contains three cysteines: C23, C45, and C106. The oxidation of
Cys106 in apoptosis abolishes the ability of HMGB1 to activate
dendritic cells, the specialized antigen-presenting cells that initi-
ate and direct T-cell immunity (Kazama et al., 2008). In contrast,
mutation of a single amino acid in the caspase cleavage site of
NADH dehydrogenase Fe-S protein-1 can inhibit ROS produc-
tion and restore the immune activity of released HMGB1 during
apoptosis (Kazama et al., 2008) (Figure 1C). Thus, the redox sta-
tus of HMGB1 in apoptosis appears to determine whether cell
death is tolerogenic or immunogenic.
Autophagy
Autophagy is a conserved, intracellular, lysosome-dependent
degradation process that allows the degradation and recycling of
cellular components such as proteins and organelles. Autophagy-
related genes (Atg) are essential regulators of autophagy in devel-
opment and most other stages of adult life. Homozygous genetic
knockouts of most Atg genes (e.g., Atg3, Atg5, Atg6, Atg7, Atg9,
andAtg16L1) inmice are developmentally lethal (Mizushima and
Levine, 2010). In addition to physiological function, dysfunction
of autophagy is implicated in human diseases such as autoim-
mune diseases, inflammatory diseases, and cancer. Autophagy is
upregulated in response to various stressors, including oxidative
stress. In many cases, upregulated autophagy promotes cell sur-
vival during various stress conditions, while excessive or uncon-
trolled autophagy promotes cell death in some cases (Kroemer
et al., 2010). The concept of autophagic cell death was first pre-
sented based on observations of increasedmorphological features
(e.g., accumulation of autophagic vesicles) in dying cells (Galluzzi
et al., 2012). Moreover, selective overexpression of autophagy can
cause a special type of regulated cell death termed “autosis,” which
is mediated by the Na+, K+-ATPase pump (Liu et al., 2013). This
report has led to increasing concerns about the pathogenic role of
autophagic cell death, although controversy still exists.
HMGB1 plays location-dependent roles in the induction
of autophagy. Cytoplasmic HMGB1 promotes starvation- and
oxidative stress-induced autophagy by binding Beclin-1 (Tang
et al., 2010b), a critical regulator of autophagy, as well as
apoptosis (Kang et al., 2011). Extracellular HMGB1 induces
autophagy by binding its receptor RAGE (Tang et al., 2010a).
Nuclear HMGB1 regulates autophagy by inducing expression of
heat shock protein β-1, which allows membrane dynamic traf-
ficking during autophagy and mitophagy (Tang et al., 2011a).
Like other ATGs, it was recently suggested that HMGB1-
independent autophagy exists in some tissues. The mechanisms
of the HMGB1-dependent and -independent autophagic signal-
ing pathways remain to be defined.
HMGB1 release is observed in macrophages, fibroblasts,
and cancer cells during autophagy and autophagic cell death
(Thorburn et al., 2009; Tang et al., 2010b; Dupont et al., 2011)
(Figure 1D). Superoxide dismutases (SOD), including SOD1,
SOD2, and SOD3, can efficiently catalyze the dismutation of
superoxide anions. Antioxidant (e.g., N-acetyl-L-cysteine) SOD1
RNAi, and SOD2 RNAi limit the translocation and release of
HMGB1 in starvation-induced autophagy, suggesting that oxida-
tive stress is involved in starvation-mediated HMGB1 release
(Tang et al., 2010b). Moreover, H2O2 and loss of SOD1-mediated
oxidative stress promote cytosolic HMGB1 expression and
extracellular release (Tang et al., 2011b). Inhibition of HMGB1
release or loss of HMGB1 decrease the number of autolysosomes
and autophagic flux in human and mouse cell lines under
conditions of oxidative stress (Tang et al., 2011b). Collectively,
HMGB1 appears to serve as an important autophagic sensor in
oxidative stress.
Pyroptosis
Pyroptosis is a caspase-1 or caspase-11-dependent regulated type
of cell death that plays a central role in inflammation and
immunity. According to their function, caspases are divided into
apoptotic (caspase-3, -6, -7, -8, and -9 in mammals) and inflam-
matory (caspase-1, -4, -5, -12 in humans and caspase-1, -11,
and -12 in mice) families (McIlwain et al., 2013). Compared
with caspase-11-dependent pyroptosis (Broz andMonack, 2013),
caspase-1-dependent pyroptosis is well-characterized (Bergs-
baken et al., 2009). Caspase-1 is activated during pyroptosis by
inflammasome, a large supramolecular complex largely com-
posed of dimers of the adaptor protein ASC (apoptosis-associated
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speck-like protein containing a caspase recruitment domain).
Four subfamilies of inflammasome are defined; namely, NLRP1,
NLRP3, NLRC4, and absent in melanoma 2 (AIM2). These
inflammasomes detect PAMPs and DAMPs in infection and
sterile inflammation (Schroder and Tschopp, 2010). Mitochon-
drial and NOX-mediated oxidative stress is an initial signal to
induce inflammasome activation. In particular, the generation
of ROS via NOX causes thioredoxin-interacting protein to asso-
ciate with NLRP3, which facilitates inflammasome formation
(Zhou et al., 2010). Finally, caspaspe-1 is activated by inflam-
masome and then promotes the procession and release of the
highly pro-inflammatory cytokines IL-1β and IL-18, as well as
HMGB1. Inhibition of inflammasome activation decreases serum
HMGB1 level and protects against liver ischemic injury and pan-
creatitis (Kamo et al., 2013).Interestingly, HMGB1 can activate
NLRP3 and AIM2 inflammasome after binding various DNA in a
TLR9- or RAGE-dependent manner, suggesting a feedback loop
between HMGB1 and inflammasome (Tian et al., 2007). Alter-
natively, HMGB1 endocytosis results in NLRP3 inflammasome-
independent and lysosome-dependent caspase-1 activation (Xu
et al., 2014a). Thus, HMGB1 acting through different signaling
pathways sequentially induces pyroptosis.
Like all caspases, caspase-1 can recognize a unique cleavage
site in substrate. A recent study identified that HMGB1 is a
direct substrate of caspase-1, but not other caspases (-2, -3, -
5, -7, -9, or -11) (Leblanc et al., 2014). In contrast to HMGB1
oxidization-mediated immune tolerance in apoptosis following
caspase-3 and -7 activation (Kazama et al., 2008), HMGB1 cleav-
age by caspapse-1 generates an active A-box peptide and then
induces inflammation by RAGE (Leblanc et al., 2014). These find-
ings suggest that activation of different caspapses determines the
immune activity of HMGB1 in death. In addition to the clas-
sical inflammasome components, PKR is a novel binding pro-
tein of inflammasome to regulate inflammation. Inhibition of
PKR expression or activity inhibits inflammasome activation and
HMGB1 release in macrophages (Lu et al., 2012) (Figure 1E).
Mitophagy or autophagy generally inhibits inflammasome acti-
vation by inhibition of mitochondrial ROS production or direct
degradation of the core components of inflammasome, respec-
tively (Nakahira et al., 2011; Deretic et al., 2013). Correlations
between autophagy, pyroptosis, and DAMP release have not yet
been studied in human disease.
NETosis
NETosis is a antimicrobial cell death that occurs primarily in
polymorphonuclear leukocytes or neutrophils in response to
infection (Remijsen et al., 2011). The discovery of neutrophil
extracellular traps (NETs), DNA-protein structures released
by neutrophils (Brinkmann et al., 2004), was originally stud-
ied. NETs can capture and kill invading microorganisms and
pathogens without using the mechanism of phagocytosis. In
addition to infection and PAMPs (e.g., lipopolysaccharide), sev-
eral cytokines (e.g., IL-8 and tumor necrosis factor) and DAMPs
(e.g., uric acid) can induce NET formation in neutrophils and
immune cells (Brinkmann and Zychlinsky, 2012; Yipp and
Kubes, 2013). Accumulating evidence indicates that NETs are
released in the context of cell death, a process called NETosis
(Steinberg and Grinstein, 2007). NETosis not only involves the
innate host defense, but also promotes thrombosis and I/R injury
(Martinod and Wagner, 2014; Savchenko et al., 2014). Impor-
tantly, tumor-induced neutrophils are more sensitive to NETosis
than normal neutrophils, suggesting that NETosis is involved in
cancer progression (Demers et al., 2012).
In addition to histones andDNA,HMGB1 is a nuclear compo-
nent of NETs regulated by several different mechanisms, includ-
ing autophagy (Mitroulis et al., 2011). Extracellular HMGB1
can also induce NET formation by autophagy (Tadie et al.,
2013; Maugeri et al., 2014a) and exhibits bacterial killing abil-
ity (Zetterstrom et al., 2006). ROS production by activation of
NOX contributes to NETosis (Figure 1F). Interestingly, extra-
cellular HMGB1 may directly induce NOX activation in neu-
trophils and mediate hemorrhagic shock in a TLR4-dependent
manner (Fan et al., 2007). Thus, release of HMGB1 in inflamma-
tion may amplify oxidative stress and NETosis. Although eptidy-
larginine deiminase 4-mediated histone citrullination is a critical
step to regulate histone release in NETosis and other types of cell
death, future work will address whether HMGB1 is a regulator of
eptidylarginine deiminase 4, which is required for NET-mediated
innate immunity and thrombosis.
Redox Modification of HMGB1 Activity in
Inflammation and Cell Death
In inflammation, extracellular HMGB1 has the ability to
stimulate cell migration and cytokine production in receptor-
dependent and -independent manners. This HMGB1 activ-
ity is determined by its redox status of cysteines (C23, C45,
and C106). Three redox forms of HMGB1 have been identi-
fied: all-cysteine-reduced HMGB1, disulfide HMGB1, and all-
cysteine-oxidized HMGB1. All-cysteine-reduced HMGB1 forms
a heterocomplex with C-X-C motif chemokine 12 and then
binds to C-X-C chemokine receptor type 4 to induce cell migra-
tion and inflammatory cell recruitment (Venereau et al., 2012).
Surprisingly, this all-cysteine-reduced HMGB1 can’t induce
cytokine production in immune cells. In contrast, reduced
C106 is required for binding of HMGB1 to TLR4 to trigger
cytokine release in macrophages (Yang et al., 2010). Subsequent
studies demonstrated that a disulfide bond between C23 and
C45 is also required for HMGB1’s cytokine-inducing activity
(Venereau et al., 2012; Yang et al., 2012). Finally, all-cysteine-
oxidized HMGB1 does not show cytokine or chemotactic activ-
ity (Venereau et al., 2012). However, other studies have revealed
that oxidized HMGB1 still has the ability to activate neutrophils
and vascular endothelial cells and trigger age-related inflamma-
tion (Davalos et al., 2013; Maugeri et al., 2014b). The reasons for
the discrepancies between studies are unclear, but may be the
result of differences in purity of HMGB1 redox protein prepa-
rations and the used dose. More convincing evidence is needed
to develop specific neutralizing antibody to recognize these three
different redox HMGB1 proteins or use mice with HMGB1 cys-
teine genetic mutation. Overall, the question of whether different
redox forms of HMGB1 are good or bad is inadequately framed.
In addition to inflammation, redox modifications are cru-
cial for the function of HMGB1 in DNA repair and autophagy.
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Compared with oxidized HMGB1, reduced HMGB1 exhibits
a stronger affinity for distorted DNA structures, but their
functional roles are not yet clear (Park and Lippard, 2011).
Replacement of Cys23 and/or 45 with serines did not affect
the nuclear distribution of the mutant proteins, while C106S
and triple cysteine mutations impaired nuclear localization of
HMGB1 (Hoppe et al., 2006), allowing entry of some of the
protein into the cytosol to induce autophagy (Tang et al.,
2010b). A disulfide bond between C23 and C45 is required
for binding of HMGB1 to Beclin-1 to induce autophagy (Tang
et al., 2010b). Moreover, extracellularly-reduced HMGB1 pro-
motes autophagy in a RAGE-dependent manner, whereas oxi-
dized HMGB1 triggers caspase-dependent apoptosis in cancer
cells (Tang et al., 2010a). Whether and how these redox modi-
fications of HMGB1 can affect cell-to-cell communication in the
tumor microenvironment remain to be elucidated (Kang et al.,
2013).
Conclusions
Since the discovery of HMGB1 in 1973 (Goodwin et al., 1973),
the multi-faceted HMGB1 has recently been identified as an
important mediator of infection and sterile inflammation, which
has initiated a new field of translational medicine for target-
ing HMGB1 in disease (Kang et al., 2014a). What lies ahead?
An improved understanding of the underlying regulation mech-
anisms of HMGB1 expression, translocation, and release; how
HMGB1 contributes to the pathophysiology of human health and
diseases; and the development of more specific and less toxic
compounds will benefit many more patients and improve their
quality of life. In particular, oxidative stress-associated human
aging and many diseases have been increasingly recognized
as central regulators of HMGB1 biology in infection, sterile
inflammation, and cell death types such as necrosis, apopto-
sis, autophagic cell death, pyroptosis, and NETosis (Tang et al.,
2011c). Different stressors may cause different stress responses,
cell deaths, and immune responses. Activation of autophagy
possibly mediates the crosstalk between cell death, inflamma-
tion, and DAMP release during stress (Levine et al., 2011;
Deretic et al., 2013; Zhang et al., 2013; Green and Levine,
2014). Targeting HMGB1 via antioxidant compounds such as
N-acetyl-cysteine protects against inflammation-associated dis-
eases in animal experiments. However, these studies seem to con-
tradict human clinical trials in which antioxidant therapy proved
largely ineffective in treating various pathologies. One possible
reason for this is that the reactivity of ROS is orders of mag-
nitude too fast. This leaves a narrow therapeutic window for
administration of antioxidant treatment, and antioxidant ther-
apies are not effective when delivered after the acute cytokine
response has occurred. Alternatively, reducing HMGB1 release
and the inflammatory response through bolstering intracellular
enzymatic antioxidants (e.g., HO-1, SODs, and catalase) or block-
ing their enzymatic production may be an attractive strategy.
In addition to blocking HMGB1 release, HMGB1 neutralizing
antibody and A box protein can block activity of extracellular
HMGB1 in animal experiments. Further investigation is needed
to evaluate these therapies and their possible roles in clinical
practice. Although much attention has been paid to the differ-
ent modifications of HMGB1 within the past 5 years, monitor-
ing the intracellular and extracellular redox statuses of HMGB1
in disease still presents a major challenge (Antoine et al., 2014;
Janko et al., 2014). Additionally, much remains unknown about
how individual signal transduction pathways are regulated upon
activation by different redox forms of HMGB1.
Acknowledgments
We apologize to the researchers who were not referenced due
to space limitations. We thank Christine Heiner (Department of
Surgery, University of Pittsburgh) for her critical reading of the
manuscript. This work was supported by the National Institutes
of Health (NIH) (R01CA160417 to D.T.), a 2013 Pancreatic Can-
cer Action Network-AACR Career Development Award (Grant
Number 13-20-25-TANG), and a grant from theNational Natural
Sciences Foundation of China (81270616 to Y.Y.). Work per-
formed in support of findings reviewed in this manuscript was
aided by the Core Support of the University of Pittsburgh Cancer
Institute (P30CA047904).
References
Andersson, U., Antoine, D. J., and Tracey, K. J. (2014). The functions of
HMGB1 depend on molecular localization and post-translational modifica-
tions. J. Intern. Med. 276, 420–424. doi: 10.1111/joim.12309
Andersson, U., and Tracey, K. J. (2011). HMGB1 is a therapeutic target for
sterile inflammation and infection. Annu. Rev. Immunol. 29, 139–162. doi:
10.1146/annurev-immunol-030409-101323
Andrassy, M., Volz, H. C., Igwe, J. C., Funke, B., Eichberger, S. N., Kaya, Z., et al.
(2008). High-mobility group box-1 in ischemia-reperfusion injury of the heart.
Circulation 117, 3216–3226. doi: 10.1161/CIRCULATIONAHA.108.769331
Angus, D. C., and Van Der Poll, T. (2013). Severe sepsis and septic shock. N. Engl.
J. Med. 369, 840–851. doi: 10.1056/NEJMra1208623
Antoine, D. J., Harris, H. E., Andersson, U., Tracey, K. J., and Bianchi, M. E. (2014).
A systematic nomenclature for the redox states of high mobility group box
(HMGB) proteins.Mol. Med. 20, 135–137. doi: 10.2119/molmed.2014.00022
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al.
(2007). Toll-like receptor 4-dependent contribution of the immune system
to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059. doi:
10.1038/nm1622
Bell, C. W., Jiang, W., Reich, C. F. III, and Pisetsky, D. S. (2006). The extracellular
release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 291,
C1318–C1325. doi: 10.1152/ajpcell.00616.2005
Bergsbaken, T., Fink, S. L., and Cookson, B. T. (2009). Pyroptosis: host cell death
and inflammation. Nat. Rev. Microbiol. 7, 99–109. doi: 10.1038/nrmicro2070
Bianchi, M. E. (2009). HMGB1 loves company. J. Leukoc. Biol. 86, 573–576. doi:
10.1189/jlb.1008585
Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., Bachi, A., et al.
(2003). Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect
it towards secretion. Embo J. 22, 5551–5560. doi: 10.1093/emboj/cdg516
Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y.,Weiss, D. S.,
et al. (2004). Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535.
doi: 10.1126/science.1092385
Brinkmann, V., and Zychlinsky, A. (2012). Neutrophil extracellular traps: is
immunity the second function of chromatin? J. Cell Biol. 198, 773–783. doi:
10.1083/jcb.201203170
Frontiers in Physiology | www.frontiersin.org 6 April 2015 | Volume 6 | Article 93
Yu et al. Oxidative stress and HMGB1
Broz, P., and Monack, D. M. (2013). Noncanonical inflammasomes: caspase-
11 activation and effector mechanisms. PLoS Pathog. 9:e1003144. doi:
10.1371/journal.ppat.1003144
Calogero, S., Grassi, F., Aguzzi, A., Voigtlander, T., Ferrier, P., Ferrari, S., et al.
(1999). The lack of chromosomal protein Hmg1 does not disrupt cell growth
but causes lethal hypoglycaemia in newborn mice.Nat. Genet. 22, 276–280. doi:
10.1038/10338
Celona, B., Weiner, A., Di Felice, F., Mancuso, F. M., Cesarini, E., Rossi, R. L.,
et al. (2011). Substantial histone reduction modulates genomewide nucleoso-
mal occupancy and global transcriptional output. PLoS Biol. 9:e1001086. doi:
10.1371/journal.pbio.1001086
Dannappel, M., Vlantis, K., Kumari, S., Polykratis, A., Kim, C., Wachsmuth, L.,
et al. (2014). RIPK1 maintains epithelial homeostasis by inhibiting apoptosis
and necroptosis. Nature 513, 90–94. doi: 10.1038/nature13608
Davalos, A. R., Kawahara, M., Malhotra, G. K., Schaum, N., Huang, J., Ved, U.,
et al. (2013). p53-dependent release of Alarmin HMGB1 is a central mediator
of senescent phenotypes. J. Cell Biol. 201, 613–629. doi: 10.1083/jcb.201206006
Demers, M., Krause, D. S., Schatzberg, D., Martinod, K., Voorhees, J. R., Fuchs, T.
A., et al. (2012). Cancers predispose neutrophils to release extracellular DNA
traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci.
U.S.A. 109, 13076–13081. doi: 10.1073/pnas.1200419109
Deretic, V., Saitoh, T., and Akira, S. (2013). Autophagy in infection, inflammation
and immunity. Nat. Rev. Immunol. 13, 722–737. doi: 10.1038/nri3532
Ditsworth, D., Zong,W. X., and Thompson, C. B. (2007). Activation of poly(ADP)-
ribose polymerase (PARP-1) induces release of the pro-inflammatory medi-
ator HMGB1 from the nucleus. J. Biol. Chem. 282, 17845–17854. doi:
10.1074/jbc.M701465200
Dupont, N., Jiang, S., Pilli, M., Ornatowski, W., Bhattacharya, D., and Deretic, V.
(2011). Autophagy-based unconventional secretory pathway for extracellular
delivery of IL-1beta. Embo J. 30, 4701–4711. doi: 10.1038/emboj.2011.398
Duprez, L., Takahashi, N., Van Hauwermeiren, F., Vandendriessche, B., Goossens,
V., Vanden Berghe, T., et al. (2011). RIP kinase-dependent necrosis drives
lethal systemic inflammatory response syndrome. Immunity 35, 908–918. doi:
10.1016/j.immuni.2011.09.020
Fan, J., Li, Y., Levy, R. M., Fan, J. J., Hackam, D. J., Vodovotz, Y., et al. (2007).
Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role
of HMGB1-TLR4 signaling. J. Immunol. 178, 6573–6580. doi: 10.4049/jim-
munol.178.10.6573
Finkel, T., and Holbrook, N. J. (2000). Oxidants, oxidative stress and the biology of
ageing. Nature 408, 239–247. doi: 10.1038/35041687
Galluzzi, L., Vitale, I., Abrams, J.M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny,
M. V., et al. (2012). Molecular definitions of cell death subroutines: recommen-
dations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ.
19, 107–120. doi: 10.1038/cdd.2011.96
Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E.,
et al. (2002). The nuclear protein HMGB1 is secreted by monocytes via a non-
classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995–1001. doi:
10.1093/embo-reports/kvf198
Giansanti, V., Dona, F., Tillhon, M., and Scovassi, A. I. (2010). PARP inhibitors:
new tools to protect from inflammation. Biochem. Pharmacol. 80, 1869–1877.
doi: 10.1016/j.bcp.2010.04.022
Giavara, S., Kosmidou, E., Hande, M. P., Bianchi, M. E., Morgan, A., D’adda
Di Fagagna, F., et al. (2005). Yeast Nhp6A/B and mammalian Hmgb1
facilitate the maintenance of genome stability. Curr. Biol. 15, 68–72. doi:
10.1016/j.cub.2004.12.065
Goodwin, G. H., Sanders, C., and Johns, E. W. (1973). A new group of chromatin-
associated proteins with a high content of acidic and basic amino acids. Eur. J.
Biochem. 38, 14–19. doi: 10.1111/j.1432-1033.1973.tb03026.x
Green, D. R., Ferguson, T., Zitvogel, L., and Kroemer, G. (2009). Immunogenic and
tolerogenic cell death. Nat. Rev. Immunol. 9, 353–363. doi: 10.1038/nri2545
Green, D. R., and Levine, B. (2014). To be or not to be? How selective autophagy
and cell death govern cell fate. Cell 157, 65–75. doi: 10.1016/j.cell.2014.02.049
Ha, H. C., and Snyder, S. H. (1999). Poly(ADP-ribose) polymerase is a media-
tor of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. U.S.A. 96,
13978–13982. doi: 10.1073/pnas.96.24.13978
Harris, H. E., Andersson, U., and Pisetsky, D. S. (2012). HMGB1: a multifunctional
alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol.
8, 195–202. doi: 10.1038/nrrheum.2011.222
He, G. Z., Zhou, K. G., Zhang, R., Wang, Y. K., and Chen, X. F. (2012). Impact of
intestinal ischemia/reperfusion and lymph drainage on distant organs in rats.
World J. Gastroenterol. 18, 7271–7278. doi: 10.3748/wjg.v18.i48.7271
Hoppe, G., Talcott, K. E., Bhattacharya, S. K., Crabb, J. W., and Sears, J. E.
(2006). Molecular basis for the redox control of nuclear transport of the
structural chromatin protein Hmgb1. Exp. Cell Res. 312, 3526–3538. doi:
10.1016/j.yexcr.2006.07.020
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., et al. (1995). The
receptor for advanced glycation end products (RAGE) is a cellular binding site
for amphoterin. Mediation of neurite outgrowth and co-expression of rage and
amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752–25761.
doi: 10.1074/jbc.270.43.25752
Huang, H., Nace, G. W., McDonald, K. A., Tai, S., Klune, J. R., Rosborough, B. R.,
et al. (2014a). Hepatocyte specific HMGB1 deletion worsens the injury in liver
ischemia/reperfusion: a role for intracellular HMGB1 in cellular protection.
Hepatology 59, 1984–1997. doi: 10.1002/hep.26976
Huang, J., Xie, Y., Sun, X., Zeh, H. J., 3rd., Kang, R., Lotze, M. T., et al. (2014b).
DAMPs, ageing, and cancer: the ‘DAMP Hypothesis’. Ageing Res. Rev. doi:
10.1016/j.arr.2014.10.004. [Epub ahead of print].
Huebener, P., Gwak, G. Y., Pradere, J. P., Quinzii, C. M., Friedman, R., Lin, C. S.,
et al. (2014). High-mobility group box 1 is dispensable for autophagy, mito-
chondrial quality control, and organ function in vivo. Cell Metab. 19, 539–547.
doi: 10.1016/j.cmet.2014.01.014
Janko, C., Filipovic, M., Munoz, L. E., Schorn, C., Schett, G., Ivanovic-Burmazovic,
I., et al. (2014). Redox modulation of HMGB1-related signaling. Antioxid.
Redox Signal. 20, 1075–1085. doi: 10.1089/ars.2013.5179
Jiang, W., Bell, C. W., and Pisetsky, D. S. (2007). The relationship between apopto-
sis and high-mobility group protein 1 release from murine macrophages stim-
ulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J. Immunol.
178, 6495–6503. doi: 10.4049/jimmunol.178.10.6495
Jouan-Lanhouet, S., Arshad, M. I., Piquet-Pellorce, C., Martin-Chouly, C., Le
Moigne-Muller, G., Van Herreweghe, F., et al. (2012). TRAIL induces necrop-
tosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ.
19, 2003–2014. doi: 10.1038/cdd.2012.90
Kaczmarek, A., Vandenabeele, P., and Krysko, D. V. (2013). Necroptosis: the
release of damage-associatedmolecular patterns and its physiological relevance.
Immunity 38, 209–223. doi: 10.1016/j.immuni.2013.02.003
Kamo, N., Ke, B., Ghaffari, A. A., Shen, X. D., Busuttil, R. W., Cheng, G., et al.
(2013). ASC/caspase-1/IL-1beta signaling triggers inflammatory responses by
promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology
58, 351–362. doi: 10.1002/hep.26320
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., et al. (2014a).
HMGB1 in health and disease. Mol. Aspects Med. 40, 1–116. doi:
10.1016/j.mam.2014.05.001
Kang, R., Tang, D., Schapiro, N. E., Loux, T., Livesey, K. M., Billiar, T. R.,
et al. (2014b). The HMGB1/RAGE inflammatory pathway promotes pancre-
atic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33,
567–577. doi: 10.1038/onc.2012.631
Kang, R., Zeh, H. J., Lotze, M. T., and Tang, D. (2011). The Beclin 1 net-
work regulates autophagy and apoptosis. Cell Death Differ. 18, 571–580. doi:
10.1038/cdd.2010.191
Kang, R., Zhang, Q., Hou, W., Yan, Z., Chen, R., Bonaroti, J., et al.
(2014c). Intracellular Hmgb1 inhibits inflammatory nucleosome release and
limits acute pancreatitis in mice. Gastroenterology 146, 1097–1107. doi:
10.1053/j.gastro.2013.12.015
Kang, R., Zhang, Q., Zeh, H. J. III, Lotze, M. T., and Tang, D. (2013). HMGB1 in
cancer: good, bad, or both? Clin. Cancer Res. 19, 4046–4057. doi: 10.1158/1078-
0432.CCR-13-0495
Kato, S., Hussein, M. H., Kakita, H., Goto, T., Daoud, G. A., Kato, T., et al. (2009).
Edaravone, a novel free radical scavenger, reduces high-mobility group box
1 and prolongs survival in a neonatal sepsis model. Shock 32, 586–592. doi:
10.1097/SHK.0b013e3181a2b886
Kawahara, K., Hashiguchi, T., Masuda, K., Saniabadi, A. R., Kikuchi, K., Tan-
charoen, S., et al. (2009). Mechanism of HMGB1 release inhibition from
RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc. Int. J. Mol.
Med. 23, 615–620. doi: 10.3892/ijmm_00000172
Kazama, H., Ricci, J. E., Herndon, J. M., Hoppe, G., Green, D. R., and Ferguson,
T. A. (2008). Induction of immunological tolerance by apoptotic cells requires
Frontiers in Physiology | www.frontiersin.org 7 April 2015 | Volume 6 | Article 93
Yu et al. Oxidative stress and HMGB1
caspase-dependent oxidation of high-mobility group box-1 protein. Immunity
29, 21–32. doi: 10.1016/j.immuni.2008.05.013
Kim, J. B., Sig Choi, J., Yu, Y. M., Nam, K., Piao, C. S., Kim, S. W.,
et al. (2006). HMGB1, a novel cytokine-like mediator linking acute
neuronal death and delayed neuroinflammation in the postischemic
brain. J. Neurosci. 26, 6413–6421. doi: 10.1523/JNEUROSCI.3815-
05.2006
Kitahara, T., Takeishi, Y., Harada, M., Niizeki, T., Suzuki, S., Sasaki, T., et al.
(2008). High-mobility group box 1 restores cardiac function after myocar-
dial infarction in transgenic mice. Cardiovasc. Res. 80, 40–46. doi: 10.1093/
cvr/cvn163
Kroemer, G., Marino, G., and Levine, B. (2010). Autophagy and the integrated
stress response.Mol. Cell 40, 280–293. doi: 10.1016/j.molcel.2010.09.023
Lange, S. S., Mitchell, D. L., and Vasquez, K. M. (2008). High mobility group pro-
tein B1 enhances DNA repair and chromatin modification after DNA damage.
Proc. Natl. Acad. Sci. U.S.A. 105, 10320–10325. doi: 10.1073/pnas.0803181105
Lau, A., Wang, S., Jiang, J., Haig, A., Pavlosky, A., Linkermann, A., et al.
(2013). RIPK3-mediated necroptosis promotes donor kidney inflammatory
injury and reduces allograft survival. Am. J. Transplant. 13, 2805–2818. doi:
10.1111/ajt.12447
Leblanc, P. M., Doggett, T. A., Choi, J., Hancock, M. A., Durocher, Y., Frank,
F., et al. (2014). An immunogenic peptide in the A-box of HMGB1 protein
reverses apoptosis-induced tolerance through RAGE receptor. J. Biol. Chem.
289, 7777–7786. doi: 10.1074/jbc.M113.541474
Levine, B., Mizushima, N., and Virgin, H. W. (2011). Autophagy in immunity and
inflammation. Nature 469, 323–335. doi: 10.1038/nature09782
Li,W., Ashok,M., Li, J., Yang, H., Sama, A. E., andWang, H. (2007). Amajor ingre-
dient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1.
PLoS ONE 2:e1153. doi: 10.1371/journal.pone.0001153
Li, W., Zhu, S., Li, J., Assa, A., Jundoria, A., Xu, J., et al. (2011).
EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in
endotoxin-stimulated macrophages. Biochem. Pharmacol. 81, 1152–1163. doi:
10.1016/j.bcp.2011.02.015
Linkermann, A., and Green, D. R. (2014). Necroptosis. N. Engl. J. Med. 370,
455–465. doi: 10.1056/NEJMra1310050
Linkermann, A., Stockwell, B. R., Krautwald, S., and Anders, H. J. (2014). Reg-
ulated cell death and inflammation: an auto-amplification loop causes organ
failure. Nat. Rev. Immunol. 14, 759–767. doi: 10.1038/nri3743
Liu, Y., Shoji-Kawata, S., Sumpter, R. M. Jr., Wei, Y., Ginet, V., Zhang, L., et al.
(2013). Autosis is a Na+,K+-ATPase-regulated form of cell death triggered
by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc. Natl.
Acad. Sci. U.S.A. 110, 20364–20371. doi: 10.1073/pnas.1319661110
Lotze, M. T., and Tracey, K. J. (2005). High-mobility group box 1 protein
(HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5,
331–342. doi: 10.1038/nri1594
Lu, B., Nakamura, T., Inouye, K., Li, J., Tang, Y., Lundback, P., et al. (2012). Novel
role of PKR in inflammasome activation and HMGB1 release. Nature 488,
670–674. doi: 10.1038/nature11290
Luo, X., and Kraus, W. L. (2012). On PAR with PARP: cellular stress signal-
ing through poly(ADP-ribose) and PARP-1. Genes Dev. 26, 417–432. doi:
10.1101/gad.183509.111
Martinod, K., and Wagner, D. D. (2014). Thrombosis: tangled up in NETs. Blood
123, 2768–2776. doi: 10.1182/blood-2013-10-463646
Maugeri, N., Campana, L., Gavina, M., Covino, C., De Metrio, M., Panciroli,
C., et al. (2014a). Activated platelets present high mobility group box 1 to
neutrophils, inducing autophagy and promoting the extrusion of neutrophil
extracellular traps. J. Thromb. Haemost. 12, 2074–2088. doi: 10.1111/jth.12710
Maugeri, N., Rovere-Querini, P., Baldini, M., Baldissera, E., Sabbadini, M. G.,
Bianchi, M. E., et al. (2014b). Oxidative stress elicits platelet/leukocyte inflam-
matory interactions via HMGB1: a candidate for microvessel injury in sytemic
sclerosis. Antioxid. Redox Signal. 20, 1060–1074. doi: 10.1089/ars.2013.5298
McIlwain, D. R., Berger, T., and Mak, T. W. (2013). Caspase functions in cell death
and disease. Cold Spring Harb. Perspect. Biol. 5:a008656. doi: 10.1101/cshper-
spect.a008656
Mitroulis, I., Kambas, K., Chrysanthopoulou, A., Skendros, P., Apostolidou, E.,
Kourtzelis, I., et al. (2011). Neutrophil extracellular trap formation is associated
with IL-1beta and autophagy-related signaling in gout. PLoS ONE 6:e29318.
doi: 10.1371/journal.pone.0029318
Mizushima, N., and Levine, B. (2010). Autophagy in mammalian develop-
ment and differentiation. Nat. Cell Biol. 12, 823–830. doi: 10.1038/ncb
0910-823
Murakami, Y., Matsumoto, H., Roh, M., Giani, A., Kataoka, K., Morizane, Y., et al.
(2014). Programmed necrosis, not apoptosis, is a key mediator of cell loss and
DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell
Death Differ. 21, 270–277. doi: 10.1038/cdd.2013.109
Nakahira, K., Haspel, J. A., Rathinam, V. A., Lee, S. J., Dolinay, T., Lam, H. C.,
et al. (2011). Autophagy proteins regulate innate immune responses by inhibit-
ing the release of mitochondrial DNA mediated by the NALP3 inflammasome.
Nat. Immunol. 12, 222–230. doi: 10.1038/ni.1980
Pardo, M., Budick-Harmelin, N., Tirosh, B., and Tirosh, O. (2008). Antioxi-
dant defense in hepatic ischemia-reperfusion injury is regulated by damage-
associated molecular pattern signal molecules. Free Radic. Biol. Med. 45,
1073–1083. doi: 10.1016/j.freeradbiomed.2008.06.029
Park, E. J., Kim, Y. M., Park, S. W., Kim, H. J., Lee, J. H., Lee, D. U., et al. (2013).
Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol
extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7
cells and CLP-induced septic mice. Food Chem. Toxicol. 55, 386–395. doi:
10.1016/j.fct.2012.12.027
Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., Ishizaka, A.,
et al. (2004). Involvement of toll-like receptors 2 and 4 in cellular activation
by high mobility group box 1 protein. J. Biol. Chem. 279, 7370–7377. doi:
10.1074/jbc.M306793200
Park, S., and Lippard, S. J. (2011). Redox state-dependent interaction of
HMGB1 and cisplatin-modified DNA. Biochemistry 50, 2567–2574. doi:
10.1021/bi2000214
Qin, S., Wang, H., Yuan, R., Li, H., Ochani, M., Ochani, K., et al. (2006). Role of
HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637–1642.
doi: 10.1084/jem.20052203
Remijsen, Q., Kuijpers, T. W., Wirawan, E., Lippens, S., Vandenabeele, P., and
Vanden Berghe, T. (2011). Dying for a cause: NETosis, mechanisms behind
an antimicrobial cell death modality. Cell Death Differ. 18, 581–588. doi:
10.1038/cdd.2011.1
Rowell, J. P., Simpson, K. L., Stott, K., Watson, M., and Thomas, J. O. (2012).
HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactiva-
tion domain interaction, regulated by the acidic tail. Structure 20, 2014–2024.
doi: 10.1016/j.str.2012.09.004
Savchenko, A. S., Borissoff, J. I., Martinod, K., De Meyer, S. F., Gallant, M., Erpen-
beck, L., et al. (2014). VWF-mediated leukocyte recruitment with chromatin
decondensation by PAD4 increases myocardial ischemia/reperfusion injury in
mice. Blood 123, 141–148. doi: 10.1182/blood-2013-07-514992
Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002). Release of chromatin protein
HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195. doi:
10.1038/nature00858
Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821–832. doi:
10.1016/j.cell.2010.01.040
Steinberg, B. E., and Grinstein, S. (2007). Unconventional roles of the NADPH
oxidase: signaling, ion homeostasis, and cell death. Sci. STKE 2007:pe11. doi:
10.1126/stke.3792007pe11
Tadie, J. M., Bae, H. B., Jiang, S., Park, D. W., Bell, C. P., Yang, H., et al. (2013).
HMGB1 promotes neutrophil extracellular trap formation through interac-
tions with Toll-like receptor 4. Am. J. Physiol. Lung Cell. Mol. Physiol. 304,
L342–L349. doi: 10.1152/ajplung.00151.2012
Takamiya, R., Hung, C. C., Hall, S. R., Fukunaga, K., Nagaishi, T., Maeno, T., et al.
(2009). High-mobility group box 1 contributes to lethality of endotoxemia in
heme oxygenase-1-deficient mice. Am. J. Respir. Cell. Mol. Biol. 41, 129–135.
doi: 10.1165/rcmb.2008-0331OC
Tang, D., Kang, R., Cheh, C. W., Livesey, K. M., Liang, X., Schapiro,
N. E., et al. (2010a). HMGB1 release and redox regulates autophagy
and apoptosis in cancer cells. Oncogene 29, 5299–5310. doi: 10.1038/onc.
2010.261
Tang, D., Kang, R., Livesey, K. M., Cheh, C. W., Farkas, A., Loughran, P., et al.
(2010b). Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881–892.
doi: 10.1083/jcb.200911078
Tang, D., Kang, R., Livesey, K. M., Kroemer, G., Billiar, T. R., Van Houten, B.,
et al. (2011a). High-mobility group box 1 is essential for mitochondrial quality
control. Cell Metab. 13, 701–711. doi: 10.1016/j.cmet.2011.04.008
Frontiers in Physiology | www.frontiersin.org 8 April 2015 | Volume 6 | Article 93
Yu et al. Oxidative stress and HMGB1
Tang, D., Kang, R., Livesey, K. M., Zeh, H. J. 3rd, and Lotze, M. T. (2011b). High
mobility group box 1 (HMGB1) activates an autophagic response to oxidative
stress. Antioxid. Redox Signal. 15, 2185–2195. doi: 10.1089/ars.2010.3666
Tang, D., Kang, R., Xiao, W., Jiang, L., Liu, M., Shi, Y., et al. (2007a). Nuclear
heat shock protein 72 as a negative regulator of oxidative stress (hydrogen
peroxide)-induced HMGB1 cytoplasmic translocation and release. J. Immunol.
178, 7376–7384. doi: 10.4049/jimmunol.178.11.7376
Tang, D., Kang, R., Xiao, W., Zhang, H., Lotze, M. T., Wang, H., et al. (2009).
Quercetin prevents LPS-induced high-mobility group box 1 release and
proinflammatory function. Am. J. Respir. Cell Mol. Biol. 41, 651–660. doi:
10.1165/rcmb.2008-0119OC
Tang, D., Kang, R., Zeh, H. J. III, and Lotze, M. T. (2011c). High-mobility group
box 1, oxidative stress, and disease. Antioxid. Redox Signal. 14, 1315–1335. doi:
10.1089/ars.2010.3356
Tang, D., Shi, Y., Jang, L., Wang, K., Xiao, W., and Xiao, X. (2005). Heat
shock response inhibits release of high mobility group box 1 protein
induced by endotoxin in murine macrophages. Shock 23, 434–440. doi:
10.1097/01.shk.0000159556.95285.df
Tang, D., Shi, Y., Kang, R., Li, T., Xiao, W., Wang, H., et al. (2007b). Hydrogen
peroxide stimulates macrophages and monocytes to actively release HMGB1.
J. Leukoc. Biol. 81, 741–747. doi: 10.1189/jlb.0806540
Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., and Thorburn, A.
(2009). Autophagy regulates selective HMGB1 release in tumor cells that are
destined to die. Cell Death Differ. 16, 175–183. doi: 10.1038/cdd.2008.143
Tian, J., Avalos, A. M., Mao, S. Y., Chen, B., Senthil, K., Wu, H., et al. (2007).
Toll-like receptor 9-dependent activation by DNA-containing immune com-
plexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487–496. doi:
10.1038/ni1457
Tracey, K. J., and Cerami, A. (1993). Tumor necrosis factor, other
cytokines and disease. Annu. Rev. Cell Biol. 9, 317–343. doi:
10.1146/annurev.cb.09.110193.001533
Tsoyi, K., Lee, T. Y., Lee, Y. S., Kim, H. J., Seo, H. G., Lee, J. H.,
et al. (2009). Heme-oxygenase-1 induction and carbon monoxide-releasing
molecule inhibit lipopolysaccharide (LPS)-induced high-mobility group box
1 release in vitro and improve survival of mice in LPS- and cecal ligation
and puncture-induced sepsis model in vivo.Mol. Pharmacol. 76, 173–182. doi:
10.1124/mol.109.055137
Tsung, A., Klune, J. R., Zhang, X., Jeyabalan, G., Cao, Z., Peng, X., et al. (2007).
HMGB1 release induced by liver ischemia involves Toll-like receptor 4 depen-
dent reactive oxygen species production and calcium-mediated signaling.
J. Exp. Med. 204, 2913–2923. doi: 10.1084/jem.20070247
Tsung, A., Sahai, R., Tanaka, H., Nakao, A., Fink, M. P., Lotze, M. T., et al.
(2005). The nuclear factor HMGB1 mediates hepatic injury after murine liver
ischemia-reperfusion. J. Exp. Med. 201, 1135–1143. doi: 10.1084/jem.20042614
Tsung, A., Tohme, S., and Billiar, T. R. (2014). High-mobility group box-1 in sterile
inflammation. J. Intern. Med. 276, 425–443. doi: 10.1111/joim.12276
Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., and Van-
denabeele, P. (2014). Regulated necrosis: the expanding network of non-
apoptotic cell death pathways. Nat Rev Mol Cell Biol 15, 135–147. doi:
10.1038/nrm3737
Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De
Marchis, F., et al. (2012). Mutually exclusive redox forms of HMGB1 pro-
mote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209,
1519–1528. doi: 10.1084/jem.20120189
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J.,
et al. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science
285, 248–251. doi: 10.1126/science.285.5425.248
Wang, H., Ward, M. F., and Sama, A. E. (2014). Targeting HMGB1 in
the treatment of sepsis. Expert Opin. Ther. Targets 18, 257–268. doi:
10.1517/14728222.2014.863876
Wang, H., Zhu, S., Zhou, R., Li, W., and Sama, A. E. (2008). Therapeutic poten-
tial of HMGB1-targeting agents in sepsis. Expert Rev. Mol. Med. 10, e32. doi:
10.1017/S1462399408000884
Wang, J., Yang, H., Hu, X., Fu, W., Xie, J., Zhou, X., et al. (2013). Dobutamine-
mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits
high mobility group box 1 protein release and attenuates rat myocar-
dial ischemia/reperfusion injury in vivo. J. Surg. Res. 183, 509–516. doi:
10.1016/j.jss.2013.02.051
Wu, H., Ma, J., Wang, P., Corpuz, T. M., Panchapakesan, U., Wyburn, K. R., et al.
(2010). HMGB1 contributes to kidney ischemia reperfusion injury. J. Am. Soc.
Nephrol. 21, 1878–1890. doi: 10.1681/ASN.2009101048
Xu, J., Jiang, Y., Wang, J., Shi, X., Liu, Q., Liu, Z., et al. (2014a). Macrophage endo-
cytosis of high-mobility group box 1 triggers pyroptosis. Cell Death Differ. 21,
1229–1239. doi: 10.1038/cdd.2014.40
Xu, W., Lu, Y., Yao, J., Li, Z., Chen, Z., Wang, G., et al. (2014b). Novel
role of resveratrol: suppression of high-mobility group protein box 1 nucle-
ocytoplasmic translocation by the upregulation of sirtuin 1 in sepsis-
induced liver injury. Shock 42, 440–447. doi: 10.1097/SHK.000000000
0000225
Yanai, H., Matsuda, A., An, J., Koshiba, R., Nishio, J., Negishi, H., et al.
(2013). Conditional ablation of HMGB1 in mice reveals its protective function
against endotoxemia and bacterial infection. Proc. Natl. Acad. Sci. U.S.A. 110,
20699–20704. doi: 10.1073/pnas.1320808110
Yang, H., Hreggvidsdottir, H. S., Palmblad, K., Wang, H., Ochani, M., Li, J., et al.
(2010). A critical cysteine is required for HMGB1 binding to Toll-like receptor
4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U.S.A.
107, 11942–11947. doi: 10.1073/pnas.1003893107
Yang, H., Lundback, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi,
M. E., et al. (2012). Redox modification of cysteine residues regulates the
cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18,
250–259. doi: 10.2119/molmed.2011.00389
Yang, L., Xie, M., Yang, M., Yu, Y., Zhu, S., Hou, W., et al. (2014). PKM2 regulates
the Warburg effect and promotes HMGB1 release in sepsis. Nat. Commun. 5,
4436. doi: 10.1038/ncomms5436
Yipp, B. G., and Kubes, P. (2013). NETosis: how vital is it? Blood 122, 2784–2794.
doi: 10.1182/blood-2013-04-457671
Youn, J. H., and Shin, J. S. (2006). Nucleocytoplasmic shuttling of HMGB1 is reg-
ulated by phosphorylation that redirects it toward secretion. J. Immunol. 177,
7889–7897. doi: 10.4049/jimmunol.177.11.7889
Yun, N., Eum, H. A., and Lee, S. M. (2010). Protective role of heme oxygenase-
1 against liver damage caused by hepatic ischemia and reperfusion in rats.
Antioxid. Redox Signal. 13, 1503–1512. doi: 10.1089/ars.2009.2873
Zetterstrom, C. K., Strand, M. L., and Soder, O. (2006). The high mobility group
box chromosomal protein 1 is expressed in the human and rat testis where
it may function as an antibacterial factor. Hum. Reprod. 21, 2801–2809. doi:
10.1093/humrep/del256
Zhang, A., Mao, X., Li, L., Tong, Y., Huang, Y., Lan, Y., et al. (2014). Necrostatin-1
inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfu-
sion injury. Transpl. Int. 27, 1077–1085. doi: 10.1111/tri.12349
Zhang, Q., Kang, R., Zeh, H. J. 3rd, Lotze, M. T., and Tang, D. (2013). DAMPs and
autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy
9, 451–458. doi: 10.4161/auto.23691
Zhou, R., Tardivel, A., Thorens, B., Choi, I., and Tschopp, J. (2010). Thioredoxin-
interacting protein links oxidative stress to inflammasome activation. Nat.
Immunol. 11, 136–140. doi: 10.1038/ni.1831
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Yu, Tang and Kang. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this jour-
nal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 9 April 2015 | Volume 6 | Article 93
